PCFFS
FDMT icon

Pacific Center for Financial Services’s 4D Molecular Therapeutics FDMT Stock Holding History

Pacific Center for Financial Services’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.93K Hold
207
– – ﹤0.01% 436
2025
Q4 		$1.8K Hold
207
– – ﹤0.01% 415
2025
Q3 		$1.8K Hold
207
– – ﹤0.01% 415
2025
Q2 		$768 Hold
207
– – ﹤0.01% 426
2025
Q1 		$669 Hold
207
– – ﹤0.01% 438
2024
Q4 		$1.15K Hold
207
– – ﹤0.01% 428
2024
Q3 		$2.24K Hold
207
– – ﹤0.01% 400
2024
Q2 		$4.34K Buy
+207
New +$5.19K ﹤0.01% 365

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Pacific Center for Financial Services's FDMT Position: Q1 2026 in Review

Pacific Center for Financial Services held its 4D Molecular Therapeutics (FDMT) position steady in Q1 2026 at 207 shares worth $1.93K. The position accounts for ﹤0.01% of the portfolio, ranked #436.

Pacific Center for Financial Services first reported a position in FDMT in Q2 2024 and has held it in 8 quarters since. The position peaked at $4.34K in Q2 2024. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Pacific Center for Financial Services held 207 shares of 4D Molecular Therapeutics worth $1.93K as of Q1 2026.
  • Pacific Center for Financial Services left its 4D Molecular Therapeutics share count unchanged in Q1 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of Pacific Center for Financial Services's portfolio in Q1 2026, its #436 holding.
  • Pacific Center for Financial Services first reported a position in 4D Molecular Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Pacific Center for Financial Services's 4D Molecular Therapeutics position peaked at $4.34K in Q2 2024.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Pacific Center for Financial Services's 13F filing for Q1 2026, filed 12 May 2026.